John Falcone
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1144682568
Payments from drug & device makers
Across 457 payments — averaging $53.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$16K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$940
- Mannkind Corporation$780
- AbbVie$778
- Boehringer Ingelheim$710
- plus $4K from 39 others
What the payments were for
- Speaking & faculty fees$13,82556%
- Travel & lodging$7263%
- Food & beverage$9,88340%
- Education$440%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,537 in reported general payments places this provider in the 80th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 378 | $447,507 |
| OzempicSemaglutide | 108 | $107,237 |
| XyostedTestosterone Enanthate | 24 | $13,965 |
| TradjentaLinagliptin | 21 | $11,178 |
| SynthroidLevothyroxine Sodium | 49 | $2,232 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 19 | $1,212 |
| Metformin Hcl ErMetformin Hcl | 47 | $457 |
| Testosterone | 11 | $438 |
| Metformin Hcl | 34 | $413 |
| CytomelLiothyronine Sodium | 12 | $234 |
| Levothyroxine Sodium | 25 | $209 |
| Atorvastatin Calcium | 14 | $94 |
| Glipizide | 11 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $15,817 | $447,507378 claims |
| Novo NordiskOzempic | $1,046 | $107,237108 claims |
| Antares Pharma, Inc.Xyosted | $474 | $13,96524 claims |
| Boehringer IngelheimTradjenta | $710 | $11,17821 claims |
| AbbVieSynthroid | $778 | $2,23249 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $110 | $20925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in New York
- Anastasios ManessisNew York$4.4M
- Adi CohenNew York$2.5M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Henry GinsbergNew York$1M
- John BilezikianNew York$814K
- Eliza GeerNew York$760K
- Christoph BuettnerNew York$709K
- Emily SteinNew York$489K
- Jason BakerNew York$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.